Novel BCR-ABL1 fusion and leukemic mutations of SETBP1, PAX5, and TP53 detected by next generation sequencing in chronic myeloid leukemia.
Patients with BCR-ABL1 fusion genes are potential candidates for targeted therapy with tyrosine kinase inhibitor (TKI) imatinib. However, novel BCR-ABL1 fusion variants can be undetected by qRT-PCR-based routine molecular screening, affecting immediate patient management and proper treatment selection. In this study, we describe a case of chronic myeloid leukemia (CML) harboring a novel BCR-ABL1 variant gene. Although Fluorescent In situ Hybridization (FISH) analysis suggested Philadelphia (Ph) translocation, qRT-PCR screening failed to detect the presence of a functional fusion transcript, which is critical for selecting targeted therapy against BCR-ABL1 fusion with aberrant kinase activity. Meanwhile, G-band cytogenetic analysis was performed twice without a solid conclusion. To overcome the uncertainty whether TKIs should be used to treat this patient effectively, we performed whole genome sequencing (WGS) in a next-generation sequencing (NGS) platform and discovered an unusual e13a2-like BCR-ABL1 fusion with 9 ABL1 intron 1 nucleotides incorporated into the broken BCR exon 13 to form a novel chimeric exon, which has never been described previously based on the best of our knowledge. Based on FISH and NGS results, the patient was treated with imatinib, showing significant improvement. Moreover, we also detected novel genetic mutations in the known leukemic genes SETBP1, PAX5, and TP53, while their role in the leukemogenesis remains to be determined. In summary, we have identified BCR-ABL1 fusion and other genetic mutations in a diagnostically difficult case of CML, demonstrating that NGS is a powerful diagnostic tool when routine procedures are challenged.
a Hematology Laboratory , Shengjing Hospital of China Medical University , Shenyang, Liaoning , China.
Shuang
S
Fu
a Hematology Laboratory , Shengjing Hospital of China Medical University , Shenyang, Liaoning , China.
Yanping
Y
Hu
a Hematology Laboratory , Shengjing Hospital of China Medical University , Shenyang, Liaoning , China.
Yu
Y
Fu
a Hematology Laboratory , Shengjing Hospital of China Medical University , Shenyang, Liaoning , China.
Fang
F
Chen
a Hematology Laboratory , Shengjing Hospital of China Medical University , Shenyang, Liaoning , China.
Xuan
X
Liu
a Hematology Laboratory , Shengjing Hospital of China Medical University , Shenyang, Liaoning , China.
Minyu
M
Zhang
a Hematology Laboratory , Shengjing Hospital of China Medical University , Shenyang, Liaoning , China.
Xiaohui
X
Wang
b Shanghai Yuanqi Bio-pharmaceutical Company Ltd , Shanghai , China.
Shichun
S
Tu
a Hematology Laboratory , Shengjing Hospital of China Medical University , Shenyang, Liaoning , China.
Jihong
J
Zhang
BCR-ABL1; PAX5; SETBP1; TP53; chronic myeloid leukemia; gene rearrangement; imatinib; next-generation sequencing; targeted therapy; tyrosine kinase inhibitor